CDC is partnering with commercial laboratories to conduct and publish results of a seroprevalence survey that has tested de-identified clinical blood specimens for SARS-CoV-2 antibodies. The survey includes people who had blood specimens tested for reasons unrelated to COVID-19, such as for a routine or sick visit during which blood was collected and tested by commercial laboratories in participating areas from each of the 10 sites. CDC aims to test about 1,800 samples collected from each of 10 areas, approximately every 3–4 weeks.
Centers for Disease Control and Prevention (CDC) no longer provides access to the data set. The image below represents an archived version of when the data set was accessible.
Identifier | URL:https://covid.cdc.gov/covid-data-tracker/#serology-surveillance |
Type | data set |
Biological Scale | population |
Collection End Date | 2020/07/30 |
Language | English |
Topics | |
Geographical Scope | Louisiana, Utah, Minnesota, Washington, Florida, Connecticut, Missouri, California, Pennsylvania, New York |
Geographical Resolution | City, State |
Start Date | 2020/03/23 |
End Date | |
Version | unspecified |
Accessible For Free | TRUE |
License | unspecified |
Rights | unspecified |
HTTP Status Code | NA |
HTTP Checked On | NA |